IMI announces three new skin sterol patents

IMI announces three new skin sterol patents 


TORONTO, June 21  /PRNewswire-FirstCall/ -- Leading predictive medicine company
IMI International Medical Innovations Inc. (TSX: IMI; Amex: IME) today
announced it has been awarded three new patents related to PREVU(x) Skin Sterol
Test, the company's non-invasive, predictive test for cardiovascular disease.

A patent titled Multilayer Analytical Element, which describes a "thin film"
that could lead to new film-based techniques for determining the amount of
cholesterol in skin tissues, was granted in Mexico. This patent has been
granted in the United States, Canada, Europe, China, Australia and Korea, and
is pending in Japan and Brazil. Additionally, a patent titled Method of
Determining Skin Tissue Cholesterol, which describes an alternative method of
using reagents for the measurement of cholesterol on the skin surface, was
allowed in Canada and Japan. This patent has been granted in the United States
and is pending in Europe.

"These latest patents further protect our skin sterol technology and bolster
our intellectual property portfolio internationally," said Dr. Brent Norton,
President and Chief Executive Officer. "Our strategy is to control and develop
all relevant technologies that could be applied to skin sterol, which ensures
that we can continue to build upon this innovative product line."

IMI maintains a diverse portfolio of intellectual property, such as trademarks,
trade secrets, and technological know-how. IMI's intellectual property
portfolio currently includes 36 issued patents and patents pending related to
the skin sterol technology, 23 patents and patents pending related to IMI's
cancer technologies and nine patents and patents pending related to the color
measurement process.

About IMI

IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases. IMI's
cardiovascular products, which are branded as PREVU(x) Skin Sterol Test, are
marketed and distributed worldwide by McNeil Consumer Healthcare, Canada. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. IMI's head office is located in Toronto, and its research and
product development facility is at McMaster University in Hamilton, Ontario.
For further information, please visit http://www.imimedical.com/. For more
information about PREVU(x), please visit http://www.prevu.com/.

Corporate Name Change

In September 2005, IMI will change its corporate name to PreMD Inc. to better
reflect the company's leading position in the predictive medicine field. The
new website will be http://www.premdinc.com/.

This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-
looking statements. Such risks and uncertainties include, among others, the
successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the Company to
take advantage of business opportunities, uncertainties related to the
regulatory process, the inability of the Company to change its name to PreMD
Inc. in the time projected due to any reason, and general changes in economic
conditions.

In addition, while the Company routinely obtains patents for its products and
technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks
and uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. IMI is providing
this information as of the date of this press release and does not undertake
any obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise. 

DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: Company Contact: Sarah Borg-Olivier, Director, Communications,

T: [phone], ; U.S. Investor Contact: Andrea

Faville, John Nesbett, The Investor Relations Group, T: [phone],

,

Copyright